After Arvinas recently provided its Q3 business and financial update, Capital One highlighted several 2024 catalysts expected for Arvinas’ Breast Cancer program vepdegestrant, including the readout of its Phase 3 monotherapy study in 2024 and an update at SABCS next month. With multiple vepdegestrant catalysts expected during 2024, as well as the entry of two new programs into the clinic during 2024, the firm believes that the current stock price “provides an excellent opportunity” and keeps an Overweight rating and $80 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN: